Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

Pfizer (PFE) stock gains as company appoints James List, a former J&J (JNJ) executive as Chief Internal Medicine Officer to ...

Essex Investment Management Co. LLC cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 16.0% in the fourth quarter, ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the ...

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

There is no better period, given the volatility in the markets today, to rotate assets into dividend stocks, said Steven ...

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to ...

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Pfizer (PFE) announced that James List has joined the company as Chief Internal Medicine Officer. List will oversee Pfizer’s Internal Medicine ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Uniondale-based McHugh Furnishings, a provider of specialty furnishings for education, healthcare, entertainment and ...